Efficacy of N-Acetylcysteine in Improving/Normalizing ALT & AST in Patients of NAFLD

Sponsor
Dow University of Health Sciences (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05576428
Collaborator
(none)
100
2
6.4

Study Details

Study Description

Brief Summary

Currently researches are focusing on the effect of antioxidants in the treatment of non-alcoholic fatty liver disease (NAFLD). Since N-acetyl cysteine (NAC) has been proven to have antioxidant and anti-inflammatory properties, therefore, we will conduct this study to determine the effect of NAC in patients of NAFLD with raised liver enzymes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Diet and exercise
  • Drug: NAC with diet and exercise
N/A

Detailed Description

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing globally, and presents a challenge for the medical community since it has no FDA approved treatment. An important feature of non-alcoholic fatty liver disease (NAFLD) is hepatic steatosis leading to hepatic dysfunction . It has been reported that NAFLD patients with increased liver enzymes have a greater risk of developing complications like cirrhosis and end-stage liver disease. since N-acetyl cysteine (NAC) has been proven to have antioxidant and anti-inflammatory properties, therefore, we will conduct this study to determine the effect of NAC in patients of NAFLD with raised liver enzymes (ALT, AST). Patients presenting with ultrasound showing fatty liver with raised liver enzymes will be recruited. They will be randomized into two groups (group A and group B).

The odd number patients will be allocated group A and even number patients will be allocated to group B.

Group A: patients in this group will be advised to follow a diet plan & daily 20 minutes brisk walking.

Group B: Patients in this group will be given NAC 200mg BD along with diet plan & exercise. This drug will be provided to the patients by the investigators free of cost.

The liver function tests and side effects of NAC will be followed at 12 weeks .

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of N-Acetylcysteine in Improving/Normalizing ALT & AST in Patients of NAFLD
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Apr 30, 2023
Anticipated Study Completion Date :
May 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: DIET& EXERCISE

diet plan & daily 20 minutes brisk walking.

Behavioral: Diet and exercise
diet and exercise in patients of NAFLD

Experimental: N Acetylcysteine WITH DIET & EXERCISE

NAC 200mg BD along with diet plan & exercise.

Behavioral: Diet and exercise
diet and exercise in patients of NAFLD

Drug: NAC with diet and exercise
NAC with diet and exercise in patients of NAFLD

Outcome Measures

Primary Outcome Measures

  1. Change in Alanine transaminase,aspartate aminotransferase [12 weeks]

    Change in Alanine transaminase,aspartate aminotransferase

Secondary Outcome Measures

  1. Side Effects of NAC [12 weeks]

    Side Effects of NAC

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • • Patients of both genders between the ages of 20 years and 60 years, giving consent to be included in the study.

  • Patients having fatty liver on ultrasound with raised ALT and AST levels

Exclusion Criteria:
  • • Patients having other causes of steatosis eg, excessive alcohol consumption,

  • Patients taking steatogenic medications such as, methotrexate , corticosteroids etc.

  • Patients suffering from other diseases that could increase ALT levels eg. Viral hepatitis, HIV, autoimmune liver diseases, infiltrative liver diseases.

  • Patients suffering from malignancies.

  • Patients who are not compliant to the medicine.

  • Pregnant and nursing females

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Dow University of Health Sciences

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tazeen Rasheed, Associate Professor, Dow University of Health Sciences
ClinicalTrials.gov Identifier:
NCT05576428
Other Study ID Numbers:
  • NAFLD-NAC
First Posted:
Oct 12, 2022
Last Update Posted:
Oct 28, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 28, 2022